GleamWall
中文EN

PBYI PUMA BIOTECHNOLOGY, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401667 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.4%
TTM net income YoY-35.6%
TTM EPS YoY-38.7%
Revenue 3-yr CAGR0.4%
Net income 3-yr CAGR85.8%

Margins

Gross margin73.6%
Operating margin11.3%
Net margin10.3%
FCF margin19.9%
EBITDA margin15.7%

Returns

ROE18.2%
ROA11.7%
ROIC (approx.)26.1%
Asset turnover1.14x

Leverage & solvency

Liabilities / assets27.7%
Debt / equity0.00x
Current ratio3.03x
Interest coverage12.88x

Cash quality & payout

Operating cash flow / net income1.93x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue-0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$228.37M$230.47M$235.64M$228.03M$253.16M
Cost of revenue$58.16M$64.40M$62.68M$55.09M$63.70M
Gross profit$170.21M$166.06M$172.96M$172.94M$189.45M
R&D expense$62.07M$54.94M$50.38M$52.24M$71.87M
SG&A expense$70.85M$80.16M$89.93M$89.98M$116.29M
Operating income$37.30M$30.97M$32.64M$23.72M$1.29M
Interest expense$6.62M$12.45M$13.33M$11.59M$12.81M
Pretax income$35.78M$24.10M$22.67M$457,000-$28.80M
Income tax$4.67M-$6.18M$1.08M$455,000$324,000
Net income$31.11M$30.28M$21.59M$2,000-$29.13M
EBITDA$48.24M$42.49M$44.16M$33.56M$12.60M
EPS (basic)0.620.620.460.00-0.72
EPS (diluted)0.610.620.450.00-0.72
Weighted avg. shares (diluted)50.65M49.10M47.55M44.93M40.64M
Balance sheet
Cash & equivalents$29.64M$69.22M$84.58M$76.20M$63.13M
Short-term investments$67.89M$31.75M$11.35M$4.87M$18.98M
Receivables$53.65M$32.01M$47.84M$40.35M$32.53M
Inventory$5.51M$8.72M$7.08M$4.53M$7.11M
Current assets$162.69M$147.66M$156.19M$134.28M$140.02M
PP&E, net$187,000$515,000$855,000$1.15M$1.76M
Intangibles$41.39M$51.13M$60.87M$70.61M$66.12M
Total assets$216.30M$213.33M$230.53M$222.06M$226.59M
Current liabilities$81.25M$96.11M$99.38M$77.48M$109.59M
Short-term debt$22.52M$45.33M$34.00M$0$0
Long-term debt$0$21.72M$65.66M$98.31M$97.09M
Total debt$22.52M$67.05M$99.66M$98.31M$97.09M
Total liabilities$85.96M$121.21M$177.09M$200.45M$229.03M
Shareholders' equity$130.34M$92.12M$53.44M$21.61M-$2.45M
Net debt-$7.11M-$2.17M$15.07M$22.11M$33.96M
Shares outstanding50.41M49.11M47.65M46.35M41.18M
Cash flow statement
Operating cash flow$41.80M$38.92M$27.01M-$15.83M$20.65M
Capital expenditure$71,000$56,000$140,000$0$0
Free cash flow$41.73M$38.86M$26.87M-$15.83M$20.65M
Investing cash flow-$36.19M-$20.44M-$19.12M$7.10M-$10.88M
Financing cash flow-$45.20M-$33.85M$0$12.22M-$31.93M
Depreciation & amortization$10.94M$11.52M$11.52M$9.84M$11.30M
Stock-based compensation$6.94M$8.24M$10.25M$11.83M$32.63M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.